Thoracic computed tomography in patients with ANCA-associated vasculitis according to ANCA serotype. Values are n (%) unless otherwise specified.
| Variables | n = 129 | PR3-ANCA, n = 81 | MPO-ANCA, n = 48 | p |
|---|---|---|---|---|
| Normal study | 28 (22) | 19 (24) | 9 (19) | 0.5 |
| Parenchymal involvement | ||||
| Consolidation | 12 (9) | 7 (9) | 5 (10) | 0.7 |
| Ground glass opacity | 21 (16) | 10 (12) | 11 (23) | 0.2 |
| Distribution | 0.2 | |||
| Diffuse | 5 (4) | 3 (4) | 2 (4) | |
| Central | 0 (0) | 0 (0) | 0 (0) | |
| Peripheral | 2 (2) | 0 (0) | 2 (4) | |
| Subpleural sparing | 14 (11) | 7 (9) | 7 (15) | |
| Reticulation, peripheral | 10 (8) | 0 (0) | 10 (21) | < 0.001 |
| Honeycombing | 10 (8) | 0 (0) | 10 (21) | < 0.001 |
| Nondependent atelectasis | 11 (9) | 9 (11) | 2 (4) | 0.2 |
| Nodular opacities | 32 (25) | 24 (30) | 8 (17) | 0.09 |
| Nodules with cavitation | 13 (10) | 13 (16) | 0 (0) | 0.002 |
| Bronchiectasis | 27 (21) | 12 (15) | 15 (31) | 0.02 |
| Severity | 0.01 | |||
| Mild | 21 (16) | 11 (14) | 10 (21) | |
| Moderate | 4 (3) | 0 (0) | 4 (8) | |
| Severe | 2 (2) | 1 (1) | 1 (2) | |
| Distribution | 0.03 | |||
| Cylindrical | 25 (19) | 11 (14) | 14 (29) | |
| Cystic | 1 (1) | 0 (0) | 1 (2) | |
| Cylindrical and cystic | 1 (1) | 1 (1) | 0 (0) | |
| Peribronchial thickening | 9 (7) | 5 (6) | 4 (8) | 0.7 |
| Bronchial stenosis, subglottic | 5 (4) | 5 (6) | 0 (0) | 0.1 |
| Central airway disease | 9 (7) | 9 (11) | 0 (0) | 0.01 |
| Emphysema | 16 (12) | 10 (12) | 6 (13) | 0.9 |
| Centrilobular | 15 (12) | 10 (12) | 5 (10) | |
| Paraseptal | 1 (1) | 0 (0) | 1 (2) | |
| Emphysema GRADE | 0.3 | |||
| < 5–25% | 7 (5) | 5 (6) | 2 (4) | |
| 26–50% | 4 (3) | 3 (4) | 1 (2) | |
| 51–75% | 4 (3) | 1 (1) | 3 (6) | |
| > 75% | 1 (1) | 1 (1) | 0 (0) | |
| Disease pattern | ||||
| Usual interstitial pneumonitis | 10 (8) | 0 (0) | 10 (21) | < 0.001 |
| Pulmonary hemorrhage | 19 (15) | 10 (12) | 9 (19) | 0.3 |
| Scarring | 13 (10) | 10 (12) | 3 (6) | 0.2 |
| Peribronchovascular nodularity | 27 (21) | 22 (27) | 5 (10) | 0.02 |
| Pulmonary venous congestion | 10 (8) | 4 (5) | 6 (13) | 0.1 |
| Additional features | ||||
| Endoluminal plugging | 4 (3) | 2 (3) | 2 (4) | 0.6 |
| Pleural effusion | 26 (20) | 13 (16) | 13 (27) | 0.1 |
| Bilateral | 19 (15) | 11 (14) | 8 (17) | |
| Unilateral | 7 (5) | 2 (2) | 5 (10) | |
| Pericardial effusion | 6 (5) | 4 (5) | 2 (4) | 1.0 |
| Lymph node enlargement, ≥ 10 mm | 18 (14) | 9 (11) | 9 (19) | 0.2 |
ANCA: antineutrophil cytoplasmic antibodies; PR3: proteinase 3; MPO: myeloperoxidase; GRADE: Grading of Recommendations Assessment, Development, and Evaluation working group.